­Nevro to Report Fourth Quarter and Full Year 2019 Financial Results

REDWOOD CITY, Calif., Feb. 3, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 25, 2020.

Investors interested in listening to the conference call may do so by dialing [phone] in the U.S. or [phone] internationally, using Conference ID: 1864387.  In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
650-433-3247
[e-mail]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-fourth-quarter-and-full-year-2019-financial-results-300997341.html

SOURCE Nevro Corp.

Copyright 2020 PR Newswire